[
  {
    "ts": null,
    "headline": "The Day Pharma’s Weight-Loss Gold Rush Intensified",
    "summary": "Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma’s hottest.",
    "url": "https://finnhub.io/api/news?id=d657f5695c9ab44a0cf33b94028a1c553fc3d4771abca67a7397bcf0134c1c87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761861600,
      "headline": "The Day Pharma’s Weight-Loss Gold Rush Intensified",
      "id": 137274979,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma’s hottest.",
      "url": "https://finnhub.io/api/news?id=d657f5695c9ab44a0cf33b94028a1c553fc3d4771abca67a7397bcf0134c1c87"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "1329 ET – Eli Lilly’s direct channel sales are reducing obstacles to access GLP-1 drugs, helping it grow the total market, the company says on its analyst call.  “There is significant demand in the consumer segment related to finding ways to get outside some of the frictions in the health care system,” Lily USA President  Ilya Yuffa  says.  “We’re seeing significantly more volume go through a direct-to-consumer platform with Lilly Direct.”",
    "url": "https://finnhub.io/api/news?id=f33991926f85a25d66e2ba519d203e2a7eb5dc536fa19b9b0961682cfba138a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761859380,
      "headline": "Health Care Roundup: Market Talk",
      "id": 137271918,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "1329 ET – Eli Lilly’s direct channel sales are reducing obstacles to access GLP-1 drugs, helping it grow the total market, the company says on its analyst call.  “There is significant demand in the consumer segment related to finding ways to get outside some of the frictions in the health care system,” Lily USA President  Ilya Yuffa  says.  “We’re seeing significantly more volume go through a direct-to-consumer platform with Lilly Direct.”",
      "url": "https://finnhub.io/api/news?id=f33991926f85a25d66e2ba519d203e2a7eb5dc536fa19b9b0961682cfba138a7"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Nasdaq, S&P End Sharply Lower With Meta's Plunge",
    "summary": "Stock Market Today: The Dow Jones index rises while the Nasdaq drops with Meta stock plunging. Chipotle sinks.",
    "url": "https://finnhub.io/api/news?id=f156de3bb1338a5bdf59d309d7f02a6737a417a5951257309d57d7861814a547",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761857523,
      "headline": "Stock Market Today: Nasdaq, S&P End Sharply Lower With Meta's Plunge",
      "id": 137274855,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index rises while the Nasdaq drops with Meta stock plunging. Chipotle sinks.",
      "url": "https://finnhub.io/api/news?id=f156de3bb1338a5bdf59d309d7f02a6737a417a5951257309d57d7861814a547"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: Amazon stock soars, Apple CEO predicts 'best-ever' holiday quarter, Reddit and Coinbase rise",
    "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=57323be3684b4f892853806c518e642b90d6997565f95a5839d2085ed7014801",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761856891,
      "headline": "Earnings live: Amazon stock soars, Apple CEO predicts 'best-ever' holiday quarter, Reddit and Coinbase rise",
      "id": 137274982,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=57323be3684b4f892853806c518e642b90d6997565f95a5839d2085ed7014801"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Thursday Recap: Eli Lilly, Metsera, Navan, Chipotle",
    "summary": "↘️ Chipotle Mexican Grill (CMG): The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were turning customers away from its stores. Shares slid 18% Thursday.",
    "url": "https://finnhub.io/api/news?id=4bbf27c2793dff14c063655a65d34b638856f58305d8d7e6c5dd644e29ec3b57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761856547,
      "headline": "Stocks to Watch Thursday Recap: Eli Lilly, Metsera, Navan, Chipotle",
      "id": 137271937,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↘️ Chipotle Mexican Grill (CMG): The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were turning customers away from its stores. Shares slid 18% Thursday.",
      "url": "https://finnhub.io/api/news?id=4bbf27c2793dff14c063655a65d34b638856f58305d8d7e6c5dd644e29ec3b57"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Nasdaq Hit As Meta Dives; Obesity Drug Leader Jumps (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index rises while the Nasdaq drops with Meta stock plunging. Chipotle sinks.",
    "url": "https://finnhub.io/api/news?id=8bbf7064a95a2ddb35b1d56e3b3901f496c1a2b742309e32996319011befe803",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761850202,
      "headline": "Stock Market Today: Nasdaq Hit As Meta Dives; Obesity Drug Leader Jumps (Live Coverage)",
      "id": 137268526,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index rises while the Nasdaq drops with Meta stock plunging. Chipotle sinks.",
      "url": "https://finnhub.io/api/news?id=8bbf7064a95a2ddb35b1d56e3b3901f496c1a2b742309e32996319011befe803"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly teams up with Walmart on Zepbound: CFO explains",
    "summary": "Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The pharmaceutical company also announced a partnership with Walmart (WMT) to make GLP-1s more accessible to consumers. Eli Lilly CFO Lucas Montarce joins Market Catalysts to discuss the pharmaceutical giant's earnings print and its Walmart partnership. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=ac039c366e60813dbc8e7191498f7ad764b32be8795e9fb9d0ab330173c16767",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761849000,
      "headline": "Eli Lilly teams up with Walmart on Zepbound: CFO explains",
      "id": 137268687,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The pharmaceutical company also announced a partnership with Walmart (WMT) to make GLP-1s more accessible to consumers. Eli Lilly CFO Lucas Montarce joins Market Catalysts to discuss the pharmaceutical giant's earnings print and its Walmart partnership. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=ac039c366e60813dbc8e7191498f7ad764b32be8795e9fb9d0ab330173c16767"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks.",
    "summary": "Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.",
    "url": "https://finnhub.io/api/news?id=e39b7a090e0eec2068aba93b1d63ec949615e1b36d0ab6df8490635eef07c6d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761847860,
      "headline": "Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks.",
      "id": 137268688,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.",
      "url": "https://finnhub.io/api/news?id=e39b7a090e0eec2068aba93b1d63ec949615e1b36d0ab6df8490635eef07c6d2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Trades Up, Here Is Why",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the morning session after the company reported a \"beat and raise\" quarter.",
    "url": "https://finnhub.io/api/news?id=9475820ca6b6a3c4feb2c725eeabd9d805f957d1c7261e513ba1a1e034295e7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761846642,
      "headline": "Eli Lilly (LLY) Stock Trades Up, Here Is Why",
      "id": 137268689,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the morning session after the company reported a \"beat and raise\" quarter.",
      "url": "https://finnhub.io/api/news?id=9475820ca6b6a3c4feb2c725eeabd9d805f957d1c7261e513ba1a1e034295e7c"
    }
  },
  {
    "ts": null,
    "headline": "Bidding war rises over weight loss drug that could prevent ‘Ozempic face’",
    "summary": "Two of the world’s largest pharmaceutical companies are locked in a bidding war for the maker of a weight-loss drug that could help patients avoid succumbing to “Ozempic face”.",
    "url": "https://finnhub.io/api/news?id=8b4f6425452a7156b1d7c61996cdad966e594402e364e2fb4d50f40056b0bbce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761845465,
      "headline": "Bidding war rises over weight loss drug that could prevent ‘Ozempic face’",
      "id": 137268690,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Two of the world’s largest pharmaceutical companies are locked in a bidding war for the maker of a weight-loss drug that could help patients avoid succumbing to “Ozempic face”.",
      "url": "https://finnhub.io/api/news?id=8b4f6425452a7156b1d7c61996cdad966e594402e364e2fb4d50f40056b0bbce"
    }
  },
  {
    "ts": null,
    "headline": "Novo: Risks Revisited And Potential Metsera Deal",
    "summary": "Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward trends. Click for my NVO stock update.",
    "url": "https://finnhub.io/api/news?id=27830f2759b9793824d0477e42ad7b79206c02b530e5a19ab50afb354b49e6c2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761845008,
      "headline": "Novo: Risks Revisited And Potential Metsera Deal",
      "id": 137271979,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305291/image_2158305291.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward trends. Click for my NVO stock update.",
      "url": "https://finnhub.io/api/news?id=27830f2759b9793824d0477e42ad7b79206c02b530e5a19ab50afb354b49e6c2"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera",
    "summary": "Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.",
    "url": "https://finnhub.io/api/news?id=8af455fa9e0d8536a775c224eb0d7d34578ac5959abe478c7e9e06b1b1b47dab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761844434,
      "headline": "Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera",
      "id": 137268691,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.",
      "url": "https://finnhub.io/api/news?id=8af455fa9e0d8536a775c224eb0d7d34578ac5959abe478c7e9e06b1b1b47dab"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia & Eli Lilly supercomputer will 'accelerate' drug discovery",
    "summary": "Eli Lilly (LLY) is one of Nvidia's (NVDA) many partners announced by the artificial intelligence (AI) chipmaker. The two companies are teaming up to build a supercomputer for drug discovery. Eli Lilly CFO, Lucas Montarce, explains how the partnership will help the pharmaceutical company grow. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=9aa71ed0ec86128322e5bdaa2196e666c49305aa1ecb942d2fdc07950479a0bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761844203,
      "headline": "Nvidia & Eli Lilly supercomputer will 'accelerate' drug discovery",
      "id": 137268537,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) is one of Nvidia's (NVDA) many partners announced by the artificial intelligence (AI) chipmaker. The two companies are teaming up to build a supercomputer for drug discovery. Eli Lilly CFO, Lucas Montarce, explains how the partnership will help the pharmaceutical company grow. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=9aa71ed0ec86128322e5bdaa2196e666c49305aa1ecb942d2fdc07950479a0bd"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: The Price Upside Just Increased",
    "summary": "Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.",
    "url": "https://finnhub.io/api/news?id=587c1d060d4e398effb733aa1a0593d90a126ebdee54afad7f8b4bf3b96cfb87",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761843494,
      "headline": "Eli Lilly: The Price Upside Just Increased",
      "id": 137271209,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.",
      "url": "https://finnhub.io/api/news?id=587c1d060d4e398effb733aa1a0593d90a126ebdee54afad7f8b4bf3b96cfb87"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales",
    "summary": "Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.",
    "url": "https://finnhub.io/api/news?id=342ad326ee1d88b4d17650efa8cf4bfb624f807ff71a42ccaa596d411fd0eb28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761843420,
      "headline": "Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales",
      "id": 137268693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.",
      "url": "https://finnhub.io/api/news?id=342ad326ee1d88b4d17650efa8cf4bfb624f807ff71a42ccaa596d411fd0eb28"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rises -- Blowout Earnings Smash Forecasts, Lifts 2025 Outlook",
    "summary": "Massive Earnings Surprise Sends Eli Lilly Stock Higher",
    "url": "https://finnhub.io/api/news?id=664989d8f34356dc5de3a8ce61120ca0e79bc09f0f02683d52194a2e9d2e79ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761840735,
      "headline": "Eli Lilly Stock Rises -- Blowout Earnings Smash Forecasts, Lifts 2025 Outlook",
      "id": 137268694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Massive Earnings Surprise Sends Eli Lilly Stock Higher",
      "url": "https://finnhub.io/api/news?id=664989d8f34356dc5de3a8ce61120ca0e79bc09f0f02683d52194a2e9d2e79ad"
    }
  },
  {
    "ts": null,
    "headline": "Earnings Data Deluge",
    "summary": "Earnings Data Deluge",
    "url": "https://finnhub.io/api/news?id=f63743145668cf78dcba39300389990014107e503626c20a35cccfd2a0bb9314",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761837000,
      "headline": "Earnings Data Deluge",
      "id": 137268695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Earnings Data Deluge",
      "url": "https://finnhub.io/api/news?id=f63743145668cf78dcba39300389990014107e503626c20a35cccfd2a0bb9314"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Q3 2025 Earnings Call Transcript",
    "summary": "Eli Lilly and Company (LLY) Q3 2025 Earnings Call October 30, 2025 10:00 AM EDTCompany ParticipantsMike Czapar - Director of Investor RelationsDavid Ricks -...",
    "url": "https://finnhub.io/api/news?id=8dc4f19936fed355efff056eaf01edd28bd5a2aa3b998624fecc7e257b0df319",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761835585,
      "headline": "Eli Lilly and Company (LLY) Q3 2025 Earnings Call Transcript",
      "id": 137268472,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company (LLY) Q3 2025 Earnings Call October 30, 2025 10:00 AM EDTCompany ParticipantsMike Czapar - Director of Investor RelationsDavid Ricks -...",
      "url": "https://finnhub.io/api/news?id=8dc4f19936fed355efff056eaf01edd28bd5a2aa3b998624fecc7e257b0df319"
    }
  },
  {
    "ts": null,
    "headline": "Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war",
    "summary": "Lilly said Thursday that its top-selling drugs, Mounjaro and Zepbound, brought in more than $10 billion combined during the recently completed third quarter.  Separately, Danish drugmaker Novo Nordisk announced plans to buy Metsera Inc. in a deal that could be worth up to $9 billion.",
    "url": "https://finnhub.io/api/news?id=e6c23c24894fdaf28bb6ccf21e3bc62f746e20ae622853bbc26548395ba21d7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761835152,
      "headline": "Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war",
      "id": 137268696,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly said Thursday that its top-selling drugs, Mounjaro and Zepbound, brought in more than $10 billion combined during the recently completed third quarter.  Separately, Danish drugmaker Novo Nordisk announced plans to buy Metsera Inc. in a deal that could be worth up to $9 billion.",
      "url": "https://finnhub.io/api/news?id=e6c23c24894fdaf28bb6ccf21e3bc62f746e20ae622853bbc26548395ba21d7c"
    }
  },
  {
    "ts": null,
    "headline": "Pre-markets Down on Questions: Fed, Jobs & Q3 Earnings",
    "summary": "Weekly Jobless Claims are not out again this Thursday morning, for the fifth straight week.",
    "url": "https://finnhub.io/api/news?id=e130f05ac2d18511b7de10db7ceb80b4a3045fc0b4d7a980446966981abc90f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761835080,
      "headline": "Pre-markets Down on Questions: Fed, Jobs & Q3 Earnings",
      "id": 137268697,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Weekly Jobless Claims are not out again this Thursday morning, for the fifth straight week.",
      "url": "https://finnhub.io/api/news?id=e130f05ac2d18511b7de10db7ceb80b4a3045fc0b4d7a980446966981abc90f7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company 2025 Q3 - Results - Earnings Call Presentation",
    "summary": "2025-10-30. The following slide deck was published by Eli Lilly and Company in conjunction with their 2025 Q3 earnings call.",
    "url": "https://finnhub.io/api/news?id=cea40146a414213ae3041b8e9f86bdadc76bfdcb38fe9b41ae25002a59d3e7d7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761834781,
      "headline": "Eli Lilly and Company 2025 Q3 - Results - Earnings Call Presentation",
      "id": 137268408,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "2025-10-30. The following slide deck was published by Eli Lilly and Company in conjunction with their 2025 Q3 earnings call.",
      "url": "https://finnhub.io/api/news?id=cea40146a414213ae3041b8e9f86bdadc76bfdcb38fe9b41ae25002a59d3e7d7"
    }
  },
  {
    "ts": null,
    "headline": "Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics",
    "summary": "The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://finnhub.io/api/news?id=5ababd219bcba0e804a8e11dc7b355be91790d6af08713991d5ac9732bdeeff7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761834603,
      "headline": "Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics",
      "id": 137268698,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
      "url": "https://finnhub.io/api/news?id=5ababd219bcba0e804a8e11dc7b355be91790d6af08713991d5ac9732bdeeff7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Blows Away Q3 Earnings Expectations",
    "summary": "Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded expectations while raising full-year guidance. The stock traded at $854.08 following the pre-market release, reflecting investor confidence in the company’s accelerating momentum across its core portfolio. Incretin Dominance Reshapes the Quarter Lilly’s incretin drugs drove the earnings beat. Mounjaro, ... Eli Lilly Blows Away Q3 Earnings Expectations",
    "url": "https://finnhub.io/api/news?id=6827e4874a50dc96b73feb1c662332168ec341ab5b9e7c90991f5652c9735d02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761834352,
      "headline": "Eli Lilly Blows Away Q3 Earnings Expectations",
      "id": 137268699,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded expectations while raising full-year guidance. The stock traded at $854.08 following the pre-market release, reflecting investor confidence in the company’s accelerating momentum across its core portfolio. Incretin Dominance Reshapes the Quarter Lilly’s incretin drugs drove the earnings beat. Mounjaro, ... Eli Lilly Blows Away Q3 Earnings Expectations",
      "url": "https://finnhub.io/api/news?id=6827e4874a50dc96b73feb1c662332168ec341ab5b9e7c90991f5652c9735d02"
    }
  },
  {
    "ts": null,
    "headline": "AI boom drives trillion-dollar tech valuations and record bets on chipmakers",
    "summary": "Nvidia’s shares jumped nearly 11% over the past month, adding about $500 billion in market value as it became the first company to reach a $5 trillion valuation.  Chief Executive Jensen Huang this week announced $500 billion in AI chip orders and plans to build seven supercomputers for the U.S. government.  Broadcom gained 17% over the past month to reach a $1.82 trillion valuation, while TSMC added 15% to $1.28 trillion and Alphabet climbed 13% to $3.32 trillion.",
    "url": "https://finnhub.io/api/news?id=0bf68e1337f5734606c6c3e744d0c39bc4e7ed08e6998ad44452fc6572fbb34f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761833319,
      "headline": "AI boom drives trillion-dollar tech valuations and record bets on chipmakers",
      "id": 137268601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Nvidia’s shares jumped nearly 11% over the past month, adding about $500 billion in market value as it became the first company to reach a $5 trillion valuation.  Chief Executive Jensen Huang this week announced $500 billion in AI chip orders and plans to build seven supercomputers for the U.S. government.  Broadcom gained 17% over the past month to reach a $1.82 trillion valuation, while TSMC added 15% to $1.28 trillion and Alphabet climbed 13% to $3.32 trillion.",
      "url": "https://finnhub.io/api/news?id=0bf68e1337f5734606c6c3e744d0c39bc4e7ed08e6998ad44452fc6572fbb34f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Smashes Expectations In 'Arguably The Strongest Print' Of The Quarter",
    "summary": "Eli Lilly stock rose early Thursday after the drugmaker easily topped third-quarter forecasts on the back of its two biggest drugs.",
    "url": "https://finnhub.io/api/news?id=5d7e24fad0a97caab093d2c78a77643fa1ad08da41aee2eaeff3d4ea0545631f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761832869,
      "headline": "Eli Lilly Smashes Expectations In 'Arguably The Strongest Print' Of The Quarter",
      "id": 137268701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock rose early Thursday after the drugmaker easily topped third-quarter forecasts on the back of its two biggest drugs.",
      "url": "https://finnhub.io/api/news?id=5d7e24fad0a97caab093d2c78a77643fa1ad08da41aee2eaeff3d4ea0545631f"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Flat to Higher Premarket Thursday",
    "summary": "Health care stocks were flat to higher premarket Thursday, with the iShares Biotechnology ETF (IBB)",
    "url": "https://finnhub.io/api/news?id=80d347c7c478d56c2cbb9d2b3cb8d907f171b2486e888e8310ac2c9c5cdbdf28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761830732,
      "headline": "Sector Update: Health Care Stocks Flat to Higher Premarket Thursday",
      "id": 137266481,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks were flat to higher premarket Thursday, with the iShares Biotechnology ETF (IBB)",
      "url": "https://finnhub.io/api/news?id=80d347c7c478d56c2cbb9d2b3cb8d907f171b2486e888e8310ac2c9c5cdbdf28"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's bid for Metsera, Eli Lilly boosts revenue outlook",
    "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Novo Nordisk's (NVO) bidding war with Pfizer (PFE) over who acquires Metsera (MTSR), Merck (MRK) cutting the higher end of its sales guidance, and Eli Lilly (LLY) raising its full-year revenue forecast after topping third quarter earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=60f388828ad12dc7bb084b4b48253c813cc0b11a8bb2ae6b33b6fa57b259f68c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761830730,
      "headline": "Novo Nordisk's bid for Metsera, Eli Lilly boosts revenue outlook",
      "id": 137266482,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Novo Nordisk's (NVO) bidding war with Pfizer (PFE) over who acquires Metsera (MTSR), Merck (MRK) cutting the higher end of its sales guidance, and Eli Lilly (LLY) raising its full-year revenue forecast after topping third quarter earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=60f388828ad12dc7bb084b4b48253c813cc0b11a8bb2ae6b33b6fa57b259f68c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Tops Earnings Forecasts and Raises Outlook as Zepbound and Mounjaro Sales Surge",
    "summary": "Strong demand for weight-loss and diabetes drugs boosts results and guidance.",
    "url": "https://finnhub.io/api/news?id=f4003265312df9e1abdbfedbc8a374eadb3c654136dfbeb29f84d5e166ff8f3b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761829773,
      "headline": "Eli Lilly Tops Earnings Forecasts and Raises Outlook as Zepbound and Mounjaro Sales Surge",
      "id": 137266483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Strong demand for weight-loss and diabetes drugs boosts results and guidance.",
      "url": "https://finnhub.io/api/news?id=f4003265312df9e1abdbfedbc8a374eadb3c654136dfbeb29f84d5e166ff8f3b"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk A/S (NVO)’s Top Investor Decides to Take Control of its Board, Reports Reuters",
    "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the Best Bargain Stocks to Buy in November. On October 22, Reuters reported that Novo Nordisk A/S (NYSE:NVO)’s top investor, the non-profit Novo Nordisk Foundation, decided to take control of the company’s board. It vowed a strong emphasis on the critical US market to fuel sales growth for Wegovy, and highlighted […]",
    "url": "https://finnhub.io/api/news?id=35455c94062f52232a922bb0898f8c396ede56e2b7338c22668b8e9eef6f9983",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761829709,
      "headline": "Novo Nordisk A/S (NVO)’s Top Investor Decides to Take Control of its Board, Reports Reuters",
      "id": 137266484,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the Best Bargain Stocks to Buy in November. On October 22, Reuters reported that Novo Nordisk A/S (NYSE:NVO)’s top investor, the non-profit Novo Nordisk Foundation, decided to take control of the company’s board. It vowed a strong emphasis on the critical US market to fuel sales growth for Wegovy, and highlighted […]",
      "url": "https://finnhub.io/api/news?id=35455c94062f52232a922bb0898f8c396ede56e2b7338c22668b8e9eef6f9983"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Raises 2025 Outlook as Third-Quarter Results Beat Estimates",
    "summary": "Eli Lilly (LLY) lifted its full-year outlook and reported third-quarter results above market expecta",
    "url": "https://finnhub.io/api/news?id=b65958658434164ede1c87f54be5a4fca78764db026df9a1302968110a7d2c2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761829306,
      "headline": "Eli Lilly Raises 2025 Outlook as Third-Quarter Results Beat Estimates",
      "id": 137266485,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) lifted its full-year outlook and reported third-quarter results above market expecta",
      "url": "https://finnhub.io/api/news?id=b65958658434164ede1c87f54be5a4fca78764db026df9a1302968110a7d2c2a"
    }
  },
  {
    "ts": null,
    "headline": "Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker.",
    "summary": "Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.",
    "url": "https://finnhub.io/api/news?id=b2169b333ae1f2320ce396807182dbc04fbfebb0fe41ec42a9f55ca10599f5db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761827820,
      "headline": "Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker.",
      "id": 137266486,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.",
      "url": "https://finnhub.io/api/news?id=b2169b333ae1f2320ce396807182dbc04fbfebb0fe41ec42a9f55ca10599f5db"
    }
  },
  {
    "ts": null,
    "headline": "5 Things to Know Before the Stock Market Opens",
    "summary": "News of the day for Oct. 30, 2025",
    "url": "https://finnhub.io/api/news?id=1ae55557a6b757dfb5b567c02750de2d38aca89ea90ec4785e73895626cd481c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761827655,
      "headline": "5 Things to Know Before the Stock Market Opens",
      "id": 137266359,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "News of the day for Oct. 30, 2025",
      "url": "https://finnhub.io/api/news?id=1ae55557a6b757dfb5b567c02750de2d38aca89ea90ec4785e73895626cd481c"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Thursday: Eli Lilly, Metsera, Navan, Microsoft",
    "summary": "↘️ Meta Platforms (META): The social-media company said it would “aggressively” raise spending to stay competitive in the artificial-intelligence arms race. That sent shares down more than 8.5% in premarket trading.",
    "url": "https://finnhub.io/api/news?id=f2fc75eb0410e65261398c78593125e759a0a1f2e24e638b65b11b190bcd491a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761827474,
      "headline": "Stocks to Watch Thursday: Eli Lilly, Metsera, Navan, Microsoft",
      "id": 137266379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↘️ Meta Platforms (META): The social-media company said it would “aggressively” raise spending to stay competitive in the artificial-intelligence arms race. That sent shares down more than 8.5% in premarket trading.",
      "url": "https://finnhub.io/api/news?id=f2fc75eb0410e65261398c78593125e759a0a1f2e24e638b65b11b190bcd491a"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Microsoft, Alphabet, Meta, Nvidia, Lilly, Chipotle, Carvana, FMC, Roblox, and More",
    "summary": "Stock futures traded mixed Thursday as investors tried to make sense of Big Tech earnings, the latest move on interest rates from the Federal Reserve, and as President Donald Trump said the U.S. would reduce tariffs on China immediately and Beijing agreed to defer its plan to tighten export controls on rare-earth materials for a year.  The software company and the second-most valuable U.S. corporation, which finished Wednesday with a market cap of $4.025 trillion, reported fiscal first-quarter adjusted earnings of $4.13 a share, better than Wall Street consensus of $3.67.  Revenue was $77.7 billion, ahead of analysts’ expectations of $75.4 billion, while Azure revenue rose by 40%, higher than forecasts of 38% growth.",
    "url": "https://finnhub.io/api/news?id=145677692f29faeb588316d7322a37d1484b718dabc990711f07e44aecd7bb7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761827280,
      "headline": "These Stocks Are Moving the Most Today: Microsoft, Alphabet, Meta, Nvidia, Lilly, Chipotle, Carvana, FMC, Roblox, and More",
      "id": 137266341,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stock futures traded mixed Thursday as investors tried to make sense of Big Tech earnings, the latest move on interest rates from the Federal Reserve, and as President Donald Trump said the U.S. would reduce tariffs on China immediately and Beijing agreed to defer its plan to tighten export controls on rare-earth materials for a year.  The software company and the second-most valuable U.S. corporation, which finished Wednesday with a market cap of $4.025 trillion, reported fiscal first-quarter adjusted earnings of $4.13 a share, better than Wall Street consensus of $3.67.  Revenue was $77.7 billion, ahead of analysts’ expectations of $75.4 billion, while Azure revenue rose by 40%, higher than forecasts of 38% growth.",
      "url": "https://finnhub.io/api/news?id=145677692f29faeb588316d7322a37d1484b718dabc990711f07e44aecd7bb7f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Blows Past Expectations On The Back Of Mounjaro, Zepbound",
    "summary": "Eli Lilly stock jumped early Thursday after the drugmaker easily topped third-quarter forecasts on the back of its two biggest drugs.",
    "url": "https://finnhub.io/api/news?id=b45983995e4c411501ea364ddac684a57fa9e3c1b18304e6719fddc258c4232b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761827097,
      "headline": "Eli Lilly Blows Past Expectations On The Back Of Mounjaro, Zepbound",
      "id": 137266490,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock jumped early Thursday after the drugmaker easily topped third-quarter forecasts on the back of its two biggest drugs.",
      "url": "https://finnhub.io/api/news?id=b45983995e4c411501ea364ddac684a57fa9e3c1b18304e6719fddc258c4232b"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera",
    "summary": "Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US rival Pfizer which called the move \"reckless\".Pfizer called Novo Nordisk's offer a \"reckless and unprecedented proposal\".",
    "url": "https://finnhub.io/api/news?id=9afe6f8db7ccee9b1e4abfcf4ec242c482c714172a44e16a032167c7cf9c6913",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761826817,
      "headline": "Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera",
      "id": 137266491,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US rival Pfizer which called the move \"reckless\".Pfizer called Novo Nordisk's offer a \"reckless and unprecedented proposal\".",
      "url": "https://finnhub.io/api/news?id=9afe6f8db7ccee9b1e4abfcf4ec242c482c714172a44e16a032167c7cf9c6913"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: Meta stock tumbles, Microsoft slides, and Alphabet jumps as Big Tech earnings pour in",
    "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=1fa07bf780600b90af7fc3d428f6241095afe7f43e3bc0c498059d8281304daf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761826759,
      "headline": "Earnings live: Meta stock tumbles, Microsoft slides, and Alphabet jumps as Big Tech earnings pour in",
      "id": 137266361,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=1fa07bf780600b90af7fc3d428f6241095afe7f43e3bc0c498059d8281304daf"
    }
  },
  {
    "ts": null,
    "headline": "Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings",
    "summary": "Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares higher.",
    "url": "https://finnhub.io/api/news?id=173c7a81ca0367f83cdacd719b8545bec433f73dceac5aa17f41f2268d72313c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761825420,
      "headline": "Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings",
      "id": 137266493,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares higher.",
      "url": "https://finnhub.io/api/news?id=173c7a81ca0367f83cdacd719b8545bec433f73dceac5aa17f41f2268d72313c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Q3 Earnings and Revenues Surpass Estimates",
    "summary": "Lilly (LLY) delivered earnings and revenue surprises of +16.61% and +9.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=b01671a22fbd94c590d995f42593bcf5a77bb4cb27b7ac7e249faaf7b8e8db88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761825303,
      "headline": "Eli Lilly (LLY) Q3 Earnings and Revenues Surpass Estimates",
      "id": 137266494,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) delivered earnings and revenue surprises of +16.61% and +9.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=b01671a22fbd94c590d995f42593bcf5a77bb4cb27b7ac7e249faaf7b8e8db88"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly ramps up orforglipron production with $1.2bn Puerto Rico site expansion",
    "summary": "The Puerto Rico facility investment comes alongside Lilly’s construction of four “mega sites” in the US.",
    "url": "https://finnhub.io/api/news?id=eaf836aec76b6899bf4819e42be2b4c9603891d8a7a38a8d57dc07a653f97693",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761825095,
      "headline": "Eli Lilly ramps up orforglipron production with $1.2bn Puerto Rico site expansion",
      "id": 137266495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Puerto Rico facility investment comes alongside Lilly’s construction of four “mega sites” in the US.",
      "url": "https://finnhub.io/api/news?id=eaf836aec76b6899bf4819e42be2b4c9603891d8a7a38a8d57dc07a653f97693"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Fall Pre-Bell as Investors Assess Trump-Xi Meeting Outcome; Powell Casts Doubt on December Rate Cut",
    "summary": "US equity markets were tracking in the red before the opening bell Thursday as traders digest the ou",
    "url": "https://finnhub.io/api/news?id=ad2da0022375fb8fcdb02d4e92e31936f6bc18878e038e9dce39b86b3c0959e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761824830,
      "headline": "Stocks Fall Pre-Bell as Investors Assess Trump-Xi Meeting Outcome; Powell Casts Doubt on December Rate Cut",
      "id": 137266363,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US equity markets were tracking in the red before the opening bell Thursday as traders digest the ou",
      "url": "https://finnhub.io/api/news?id=ad2da0022375fb8fcdb02d4e92e31936f6bc18878e038e9dce39b86b3c0959e0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly celebrates \"another strong quarter\" as profit surges",
    "summary": "Eli Lilly celebrates \"another strong quarter\" as profit surges",
    "url": "https://finnhub.io/api/news?id=2b051a8e73e84221edb488da032c7c799ccb176b60fec1a64ef3d3a09e8e58bb",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761824780,
      "headline": "Eli Lilly celebrates \"another strong quarter\" as profit surges",
      "id": 137266013,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2b051a8e73e84221edb488da032c7c799ccb176b60fec1a64ef3d3a09e8e58bb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly raises annual revenue guidance amid strong weight-loss drug demand",
    "summary": "Investing.com - Eli Lilly has lifted its full-year financial forecasts, fueled by its mega-popular obesity treatments which helped the drugmaker deliver better-than-anticipated third-quarter results.",
    "url": "https://finnhub.io/api/news?id=332f5762e622686cb064b56547881c2410c91079543497f1bd2779e249f8dc6e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761823355,
      "headline": "Eli Lilly raises annual revenue guidance amid strong weight-loss drug demand",
      "id": 137266497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com - Eli Lilly has lifted its full-year financial forecasts, fueled by its mega-popular obesity treatments which helped the drugmaker deliver better-than-anticipated third-quarter results.",
      "url": "https://finnhub.io/api/news?id=332f5762e622686cb064b56547881c2410c91079543497f1bd2779e249f8dc6e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal",
    "summary": "Shares of  Eli Lilly  climbed Thursday after the drugmaker reported third-quarter earnings that blew past expectations.  Eli Lilly  shares were up 5.6% to $859 in premarket trading Thursday.  Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate of $5.4 billion.",
    "url": "https://finnhub.io/api/news?id=aa9ec888fb6e84a874954ce2054b156ea86b801fc68753380466c81534c6252d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761822780,
      "headline": "Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal",
      "id": 137266498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of  Eli Lilly  climbed Thursday after the drugmaker reported third-quarter earnings that blew past expectations.  Eli Lilly  shares were up 5.6% to $859 in premarket trading Thursday.  Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate of $5.4 billion.",
      "url": "https://finnhub.io/api/news?id=aa9ec888fb6e84a874954ce2054b156ea86b801fc68753380466c81534c6252d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Delivers Strong Q3 Numbers, Stock Soars",
    "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 53.9% year on year to $17.6 billion. The company’s full-year revenue guidance of $63.25 billion at the midpoint came in 2.6% above analysts’ estimates. Its non-GAAP profit of $7.02 per share was 18.6% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=1f2511bd4de15e86356691f6bb5a0f0518cf99806052de856c4090605ab7d903",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761822257,
      "headline": "Eli Lilly (NYSE:LLY) Delivers Strong Q3 Numbers, Stock Soars",
      "id": 137266499,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 53.9% year on year to $17.6 billion. The company’s full-year revenue guidance of $63.25 billion at the midpoint came in 2.6% above analysts’ estimates. Its non-GAAP profit of $7.02 per share was 18.6% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=1f2511bd4de15e86356691f6bb5a0f0518cf99806052de856c4090605ab7d903"
    }
  },
  {
    "ts": null,
    "headline": "Lilly: Q3 Earnings Snapshot",
    "summary": "INDIANAPOLIS (AP) — Eli Lilly and Co. (LLY) on Thursday reported third-quarter profit of $5.58 billion. The Indianapolis-based company said it had net income of $6.21 per share. Earnings, adjusted for one-time gains and costs, were $7.02 per share.",
    "url": "https://finnhub.io/api/news?id=fa9bff14587010358ed385ffb00b323d2c368bfc92303c26eb7ddd5dd0df8790",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761821605,
      "headline": "Lilly: Q3 Earnings Snapshot",
      "id": 137266500,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "INDIANAPOLIS (AP) — Eli Lilly and Co. (LLY) on Thursday reported third-quarter profit of $5.58 billion. The Indianapolis-based company said it had net income of $6.21 per share. Earnings, adjusted for one-time gains and costs, were $7.02 per share.",
      "url": "https://finnhub.io/api/news?id=fa9bff14587010358ed385ffb00b323d2c368bfc92303c26eb7ddd5dd0df8790"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's profits soar in Q3, sending the stock higher in premarket trading",
    "summary": "In Q3 2025, Eli Lilly reported adjusted net income of $6.31bn, compared with $1.06bn a year earlier, up a massive 493%. Adjusted EPS was $7.02 vs. $1.18 a year earlier.According to published data, net...",
    "url": "https://finnhub.io/api/news?id=57e10e28637cdf3c7d9b73f52da9bb4745760fe5f1d91367da6ce8fe7efa3a8f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761808759,
      "headline": "Eli Lilly's profits soar in Q3, sending the stock higher in premarket trading",
      "id": 137265660,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "In Q3 2025, Eli Lilly reported adjusted net income of $6.31bn, compared with $1.06bn a year earlier, up a massive 493%. Adjusted EPS was $7.02 vs. $1.18 a year earlier.According to published data, net...",
      "url": "https://finnhub.io/api/news?id=57e10e28637cdf3c7d9b73f52da9bb4745760fe5f1d91367da6ce8fe7efa3a8f"
    }
  }
]